Non-Hodgkin limfom (NHL) je karcinom krvi koji nastaje u bijelim krvnim ćelijama-limfocitima, koje su ključna komponenta imunog sistema.¹ Postoji više od 60 različitih podtipova NHL,² a oni se mogu klasifikovati kao indolentni (spororastući) i agresivni (brzorastući), zavisno od brzine napredovanja karcinoma.³ Dva najčešća tipa NHL-a, folikularni limfom (FL) i difuzni B-krupnoćelijski limfom (DLBCL), veoma se razlikuju prema tome kako, kada i gdje se razvijaju, kao i prema načinu na koji se tretiraju.

Reference

  1. Lymphoma research foundation. [Internet; cited November 2018]. Available at: 

  2. Swerdlow SH, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. In: World Health Organization Classification of Tumours. Lyon, France: IARC; 2017.

  3. American Cancer Society. What is Non-Hodgkin Lymphoma. [Internet; cited November 2018]. Available at: 

  4. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909-18.

  5. Globocan 2018. World fact sheet. [Internet; cited November 2018]. Available at: 

  6. Very Well Health. [Internet; cited November 2018] Available at: 

  7. Lymphoma Action. [Internet; cited November 2018]. Available at: 

  8. Lymphoma Research Foundation. [Internet; cited November 2018]. Available at:  Last accessed September 2016

  9. Medscape. Diffuse large cell lymphoma. [Internet; cited November 2018]. Available at: 

  10. Rovira J et al. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann Hematol. 2015; 94: 803–812.

  11. Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Program 2007; 1:216-225.

  12. Lymphoma Research Foundation. [Internet; cited November 2018]. Available at: 

  13. Maurer, MJ et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014; 32: 1066-73.

  14. Vaidya R & Witzig TE. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Annals of Oncology 2014; 25:2124–2133.

  15. Fowler N. Role of Maintenance Rituximab (Rituxan) Therapy In the Treatment of Follicular Lymphoma. Pharmacy and Therapeutics; 2011; 36:590-598

  16. Dotan E, et al. Impact of rituximab (Rituxan) on the treatment of B-cell non-hodgkin’s lymphoma. Pharmacy and Therapeutics.2010;35:148-57.

Hoffmann-La Roche Ltd Representative Office Podgorica Cetinjska 11, The Capital Plaza 81000 Podgorica, Montenegro